Process Validation

FDA Warning Letter: Happy Farm Botanicals cited for component testing, stability, and validation failures

by

FDA states that its March 30 to April 2, 2026, inspection of Happy Farm Botanicals’ OTC drug facility found significant CGMP violations. The firm did not perform specific identity testing on incoming raw materials and components, including APIs, before use; one API lot received only organoleptic testing and was used in finished batches. FDA also found a lapsed supplier requalification and no adequate validation of supplier test analyses. The stability program lacked adequate chemical and microbiological support for labeled expiry periods: accelerated studies lacked controlled humidity records, several timepoints were unavailable, and failing viscosity results in accelerated and long-term studies were not investigated. FDA’s quality unit findings included absent process validation for OTC products, absent cleaning validation for non-dedicated equipment, inadequate investigation and CAPA for recurring gasket seal failures, and inappropriate API content release limits. FDA deemed the firm’s response inadequate and noted that process and cleaning validation commitments from the 2024 inspection remained incomplete. The firm reported plans to cease production of the specified drugs at this facility.

FDA Warning Letter: Fresenius cited for leaking dialysis solution bags and inadequate visual inspection controls

by

FDA inspected Fresenius USA Manufacturing’s Ogden, Utah drug facility from March 2-6, 2026, and cited significant CGMP violations involving complaint investigations, CAPA, process controls, and visual inspection of sterile injectable products. For Delflex Peritoneal Dialysis Solution, an August 2025 investigation covered 35 complaints involving approximately 156 leaking bags from multiple batches and attributed holes to printing. FDA stated that the firm assigned the lowest severity despite its matrix identifying peritonitis as a potential harm at the highest severity, did not recall then, and inadequately investigated risk and implemented CAPA. After inspection, reexamination found perforations without substantial fluid in the overwrap; the firm reassessed risk and recalled affected lots on April 6, 2026 for lack of assurance of sterility. FDA found the response still lacked sufficient CAPA to improve leak detection. FDA also found personnel qualification for visual particulate inspection inadequate because the kit was not adequately representative and records lacked sufficient detail, and said the response did not demonstrate reliable detection at an appropriate level.

FDA Warning Letter: Spa De Soleil cited for water system, component testing, validation, and quality unit deficiencies

by

FDA inspected Spa De Soleil’s Sun Valley drug manufacturing facility in January 2026 and found significant CGMP violations affecting OTC topical drug production. FDA states the firm inadequately investigated 51 water-system microbiological OOL and chemical OOS results recorded from May 2024 through July 2025, including gram-negative recoveries, conductivity failures, and total organic carbon failures. Investigations relied on resampling and retesting without identifying microorganisms or adequately evaluating affected products. The water system contained dead legs, threaded fittings, Teflon tape, and ball valves, and monitoring did not reflect production schedules. FDA also found inadequate identity and impurity testing of incoming high-risk components, including controls for methanol, DEG, and EG, plus unverified reliance on supplier certificates of analysis. Manufacturing processes lacked adequate validation, and batch records omitted critical processing parameters and equipment identification. An alternative microbiological method was not shown equivalent to or better than USP methods. FDA further cited ineffective quality-unit oversight, insufficient contract-laboratory qualification, absent annual product quality evaluations, and unvalidated cleaning procedures. The February 2026 response lacked supporting documentation and adequate corrective-action evidence; similar violations had been cited in 2021.

FDA Warning Letter: API Process Validation, Batch Records, Analytical Methods, and Stability Deficiencies

by

What happened FDA states that its records review identified significant CGMP deviations at Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd., an API manufacturer. The firm manufactured and distributed APIs to U.S. 503A compounding pharmacies without adequate process validation; it had described the APIs as still in development and said formal documents, including SOPs, were not finalized. … Read more

FDA Warning Letter: Zydus Lifesciences cited for contamination, aseptic processing, and PPQ deficiencies

by

What happened FDA inspected Zydus Lifesciences Limited in Gujarat from April 15 to 23, 2024, and cited significant CGMP violations involving investigations, aseptic processing, and process validation. FDA stated that multiple cross-contamination events over about three months were linked to inadequate cleaning of shared equipment. Investigations did not cover all potentially affected batches, equipment, product-contact … Read more